These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34931674)

  • 61. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
    Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.
    Wang ML; Tang H
    Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):579-586. PubMed ID: 27919846
    [TBL] [Abstract][Full Text] [Related]  

  • 64. HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.
    Ding WB; Wang MC; Yu J; Huang G; Sun DP; Liu L; Zhang JN; Yang Y; Liu H; Zhou WP; Yang F; Yuan SX
    Hepatology; 2021 Sep; 74(3):1480-1495. PubMed ID: 33825218
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
    J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients.
    Cho YY; Lee JH; Chang Y; Nam JY; Cho H; Lee DH; Cho EJ; Lee DH; Yu SJ; Lee JM; Kim YJ; Yoon JH
    J Viral Hepat; 2018 Oct; 25(10):1161-1171. PubMed ID: 29741286
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.
    Liang KH; Hsu CW; Chang ML; Chen YC; Lai MW; Yeh CT
    J Infect Dis; 2016 Mar; 213(6):966-74. PubMed ID: 26582959
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study.
    Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
    Eur J Intern Med; 2023 Jan; 107():66-72. PubMed ID: 36347739
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
    Tada T; Toyoda H; Yasuda S; Miyake N; Kumada T; Kurisu A; Ohisa M; Akita T; Tanaka J
    Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1452-1459. PubMed ID: 31082998
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels.
    Chang JI; Sinn DH; Cho H; Kim S; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Dig Dis Sci; 2022 Sep; 67(9):4565-4573. PubMed ID: 34800218
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.
    He D; Guo S; Chen W; Chen X; Yan G; Wang J; Li M; Zhu P; Huang H; Wang Y
    BMC Infect Dis; 2013 Oct; 13():458. PubMed ID: 24090287
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.
    Kurokawa M; Hiramatsu N; Oze T; Yakushijin T; Miyazaki M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Iio S; Doi Y; Yamada A; Oshita M; Kaneko A; Mochizuki K; Hagiwara H; Mita E; Ito T; Inui Y; Katayama K; Yoshihara H; Imai Y; Hayashi E; Hayashi N; Takehara T
    J Gastroenterol; 2012 May; 47(5):577-85. PubMed ID: 22231575
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
    Tsai HW; Lin YJ; Wu HC; Chang TT; Wu IC; Cheng PN; Yen CJ; Chan SH; Huang W; Su IJ
    Oncotarget; 2016 May; 7(19):27724-34. PubMed ID: 27027237
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Mechanism relevant to hepatocellular carcinoma occurrence after negative conversion of viral DNA in treatment of chronic hepatitis B patients with nucleos(t)ide drugs].
    Gao TJ; Han GY; Lu FM
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):905-909. PubMed ID: 31941249
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Analysis and significance of HBV DNA below the lower detection limit of HBV RNA levels after long-term NAs antiviral therapy in patients with hepatitis B virus cirrhosis].
    Wang CY; Cao Y; Feng YM; Li J; Jiang B; Zhang Y; Wen J; Zhu YJ; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jul; 30(7):758-762. PubMed ID: 36038347
    [No Abstract]   [Full Text] [Related]  

  • 78. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection.
    Lin CL; Kao JH
    Clin Mol Hepatol; 2023 Jul; 29(3):605-622. PubMed ID: 36788759
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Perspectives and control of hepatitis B virus infection in Taiwan.
    Lin CL; Kao JH
    J Formos Med Assoc; 2015 Oct; 114(10):901-9. PubMed ID: 26184565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.